Zentalis Pharmaceuticals ... (ZNTL)
NASDAQ: ZNTL
· Real-Time Price · USD
1.31
-0.04 (-2.96%)
At close: Jun 25, 2025, 3:59 PM
1.30
-1.14%
Pre-market: Jun 26, 2025, 08:36 AM EDT
-2.96% (1D)
| Bid | 1.3 |
| Market Cap | 94.62M |
| Revenue (ttm) | 26.86M |
| Net Income (ttm) | -224.19M |
| EPS (ttm) | -3.14 |
| PE Ratio (ttm) | -0.42 |
| Forward PE | -0.68 |
| Analyst | Hold |
| Ask | 1.35 |
| Volume | 381,097 |
| Avg. Volume (20D) | 833,690 |
| Open | 1.34 |
| Previous Close | 1.35 |
| Day's Range | 1.29 - 1.37 |
| 52-Week Range | 1.01 - 5.44 |
| Beta | 1.61 |
About ZNTL
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ZNTL
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ZNTL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 months ago
-21.25%
Zentalis Pharmaceuticals shares are trading lower....
Unlock content with
Pro Subscription
5 months ago
-1.08%
Zentalis Pharmaceuticals shares are trading higher after the company announced that the FDA has granted Fast Track Designation to azenosertib for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
